Ninety One Reports Decrease in Profits and Outflows

1 Mins read

Ninety One, a London-listed asset manager, has announced a decrease in pretax profit and higher outflows for the six months ended September 30. Despite facing a challenging macroeconomic environment, the company remains focused on market leadership and long-term growth.

Financial Performance

During the reporting period, Ninety One’s pretax profit fell to £104.0 million, compared to £110.6 million in the same period last year. Additionally, assets under management decreased from £132.3 billion to £123.1 billion, and revenue saw a decline from £384.3 million to £350.2 million.

Market Challenges

Ninety One attributed the decline in performance to various factors, including increased interest rates and geopolitical uncertainty. These conditions, coupled with investor caution, have dampened appetite for emerging markets and public equities. The company expects these challenges to persist throughout fiscal year 2024.

Strategic Focus

Despite the headwinds faced by the active investment management industry, Ninety One remains optimistic about regaining its growth momentum. Founder and Chief Executive, Hendrik du Toit, expressed confidence in the company’s ability to navigate these cyclical challenges. In order to achieve market leadership, Ninety One will apply strict cost discipline and maintain a long-term growth perspective.

Outflows and Dividends

Net outflows for the reporting period totaled £4.3 billion, an increase from the £3.2 billion outflows reported a year earlier. In light of current circumstances, Ninety One’s board declared an interim dividend of 5.9 pence per share, down from 6.5 pence.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

62 − 53 =